Journey Medical CORP 10-Q quarterly reports

Journey Medical Corporation's Q2 2026 results show a 23% total revenue increase driven by Emrosi, though net losses persist, raising going concern questions.

Journey Medical Corporation reported a 21% increase in total revenue for the first quarter of 2026, driven by strong performance in Emrosi, despite an overall net loss.

Journey Medical Corporation reports increased total revenue driven by the Emrosi launch, despite declines in legacy products, while extending its credit facility maturity and addressing going concern doubts.

Journey Medical Corporation reported a slight revenue increase for Q2 2025 driven by the Emrosi launch, but faces recurring losses and a 'going concern' warning.

Journey Medical Corp reports its Q1 2025 financial results, highlighting the commercial launch of Emrosi and a slight increase in total net product revenues compared to Q1 2024.

Journey Medical Corporation's Q3 2024 results show a decrease in product revenue, offset by a gain on debt extinguishment and the FDA approval of Emrosi.

Journey Medical Corporation's Q2 2024 results show a decrease in revenue and a net loss, but also a reduction in operating expenses and a new loan facility.

Journey Medical Corporation's Q1 2024 results show a 7% increase in revenue, driven by key products, alongside increased R&D spending and reduced SG&A expenses.